Bridge Point Capital Participated in Cannabis World Congress & Business Exposition 2019 Conference



Manhattan, New York, New York, June 3rd, 2019 – Gray Somers, Managing Director of Bridge Point Capital, a private equity firm dedicated to making U.S/China cross-border healthcare investments, attended the Cannabis World Congress & Business Exposition 2019 Conference (CWCB Expo) from May 29th to June 1st, at Javits Center, New York City.


The Cannabis World Congress & Business Exposition is a business-to-business trade show event for the legalized cannabis industry. It is held 3 times per year in the largest media, financial, and business markets: New York, Los Angeles, and Boston. It is the leading forum for dispensary owners, growers, suppliers, investors, medical professionals, government regulators, legal counsel, and entrepreneurs looking to achieve business success and identify new areas of growth in this dynamic and fast-growing industry.


As the former president of Anthem Blue Cross Blue Shield of New Hampshire as well as the co-founder of two successful healthcare startups in the population health and addiction treatment spaces, Gray is a passionate advocate for healthcare transformation. “While the market is still evolving rapidly, it’s clear that the therapeutic benefits associated with medical cannabis will fundamentally change the way clinicians treat a number of conditions including chronic pain, epilepsy, multiple sclerosis and PTSD.” Notably, on Friday May 31st, the FDA held an all-day hearing to solicit testimony from clinicians, industry executives, patients and other interested parties on the use of CBD. The purpose of the hearing was to help the FDA determine the need for additional oversight and possibly new regulations for CBD products. The FDA is expected to promulgate its findings later this summer.


About us:


Bridge Point Capital is a private equity firm based in New York with a focus on U.S.-China cross-border investment. We invest in disruptive late-stage healthcare companies that can benefit from penetrating the vast yet unexplored Chinese healthcare market. We aim to leverage our expertise in both healthcare and capital markets to establish a sustainable investment platform for our investors.